Belantamab is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA). Belantamab can be used in the synthesis of Belantamab mafodotin, an ADC developed for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM).